Highlights

Above

The Natural Organism Library at the Bioinformatics Institute has a huge fungal section, many of which secrete biologically active compounds. Here, the colony morphology of the fungus Trametes sanguinea grown on an agar plate is shown. It is known to produce cytotoxic compounds.

© 2018 A*STAR Bioinformatics Institute

A library with a difference

19 Dec 2018

The 160K Natural Organism Library houses a wealth of novel compounds for biological research

A library based at A*STAR containing more than 160,000 biological specimens is a treasure trove of biologically active compounds for wide ranging applications.

The 160K Natural Organism Library, at A*STAR’s Bioinformatics Institute, is one of the largest libraries of its kind in the world, housing more than 37,000 plant species, 54,000 fungi specimens, and nearly 68,000 strains of bacteria in cold storage. The collection also includes more than 340,000 organic extracts — around one-fifth of which have been chemically fingerprinted — and 2,600 compounds isolated from biological samples.

The library is also unique in that it has an in-house discovery platform to help users efficiently mine its biological riches through conventional biological high-throughput screening (testing extracts and compounds against relevant bioassays), chemi­cal screening, genomic screening, and what Frank Eisenhaber, director of the Bioinformatics Institute, calls in silico, or digital screening, which uses computational tools to look into the annotations of genomes, proteins and metabolites.

“My dream is that at some stage we will have an in silico library in addition to the physical library, so high-throughput screening is done not with the biological extracts but with the genomes in silico,” he says.

His vision is that all the genomes in the library will one day be sequenced. When that is achieved, instead of conducting labour-intensive, expensive high-throughput screening of hundreds of biological compounds, digital screening of genomes could first identify the best candidates for in vitro biological assays, and determine the optimum conditions for those assays.

“Instead of biological high-throughput screening of tens of thousands of organisms, we would run dedicated research over a couple of handfuls [of organisms],” he says.

The library itself is an amalgamation of several natural organism libraries originally held by companies and public organizations, that were entrusted to A*STAR’s Bioinformatics Institute in 2014. Its specimens have been sourced from more than 100 countries, however, there is now a focus on regional specimens, with a project to collect uniquely Singaporean strains of bacteria for the collection.

Researchers looking for new biologically-active compounds, applicable enzymes and microbes, have flocked to the library and one Asian multinational company recently launched a clinical trial for a compound sourced from it.

Frank Eisenhaber says the library’s materials attract not only the pharmaceutical sector, but also companies producing food, cosmetics and consumer care products. He envisages potential applications in such unexpected fields as construction; for example, identifying a compound that could help address fungal infestations that plague buildings in tropical regions.

The A*STAR-affiliated researchers contributing to this research are from the Bioinformatics Institute.  For more information about the team’s research, please visit the Natural Product Library page.

Want to stay up-to-date with A*STAR’s breakthroughs? Follow us on Twitter and LinkedIn!

References

Ng, S., Kanagasundaram, Y., Fan, H., Arumugam, P., Eisenhaber, B. et al.  The 160K Natural Organism Library, a unique resource for natural products research. Nature Biotechnology 36, 570-573. (2018). | article

About the Researcher

Frank Eisenhaber

Bioinformatics Institute
Frank Eisenhaber holds an MD and a degree in biophysics from the Pirogov Medical University in Moscow (1985) and a PhD from the Engelhardt Institute of Molecular Biology in Moscow. After working as PI at the Institute of Molecular Pathology (IMP) in Vienna (1999-2007), he joined the Bioinformatics Institute A*STAR Singapore in August 2007 as Executive Director. Frank Eisenhaber's research interest is focused on the discovery of new biomolecular mechanisms with theoretical and biochemical approaches and the functional characterization of yet uncharacterized genes and pathways. As mechanistic insight is the driver for biotechnology, biomedical and clinical applications, this work has catalyzed various lines of applied research. Frank Eisenhaber is one of the scientists credited with the discovery of the SET domain methyltransferases, ATGL, kleisins, many new protein domain functions (for example in the GPI lipid anchor biosynthsis pathway) and with the development of accurate prediction tools for posttranslational modifications and subcellular localizations.

This article was made for A*STAR Research by Nature Research Custom Media, part of Springer Nature